RDEA
Ardea Biosciences Inc
Biotechnology company developing treatments for gout, notably lesinurad; acquired by AstraZeneca in 2012
CUSIP: 03969P107HealthcareUS1 holder
Ardea Biosciences Inc
Biotechnology company developing treatments for gout, notably lesinurad; acquired by AstraZeneca in 2012
No insider transactions reported in the last year. Look across all recorded history →